Want to see BYSI full AI Analyst Report?
BYSI Stock Chart & Stats
$1.12
$0.05(4.46%)
At close: 4:00 PM EDT
$1.12
$0.05(4.46%)
Day’s Range― - ―
52-Week Range$0.99 - $2.44
Previous Close$1.17
Volume9.77K
Average Volume (3M)478.07K
Market Cap
$46.47M
Enterprise Value$61.59M
Total Cash (Recent Filing)$7.86M
Total Debt (Recent Filing)$246.00K
Price to Earnings (P/E)―
Beta0.11
Next Earnings
Sep 04, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.19
Shares Outstanding41,119,820
10 Day Avg. Volume1,393,566
30 Day Avg. Volume478,066
Financial Highlights & Ratios
PEG Ratio0.29
Price to Book (P/B)-2.05
Price to Sales (P/S)0.00
P/FCF Ratio-3.28
Enterprise Value/Market Cap1.33
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-3.24K
Enterprise Value/Ebitda-7.68
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)1.98
Revenue Forecast (FY)$194.65M
Bulls Say, Bears Say
Bulls Say
Lead Asset Advancing To Phase 3Plinabulin is in a confirmatory 442‑patient Phase 3 (DUBLIN‑4), which is a structural de‑risking milestone: positive Phase 3 data would enable regulatory filing and commercial pathways, materially changing cash needs and long‑term revenue potential versus earlier development stages.
New Capital‑markets And Finance LeadershipThe board appointed a CEO with capital‑markets experience and a CFO with listed‑company finance background, which strengthens the company's ability to execute a Phase 3 program, access investors, and manage complex cross‑border financing and governance — durable execution improvements.
Trend Of Narrowing Losses And Lower Cash BurnOperating losses and cash burn have meaningfully declined versus earlier years, indicating improved cost control and program efficiency. A persistent downward trend in burn provides more runway per financing event and increases the odds management can fund Phase 3 execution with fewer dilutive raises.
Bears Say
Negative Shareholder EquityShareholders' equity turned negative and has deteriorated to roughly -$32M, reflecting cumulative losses and asset drawdown. Negative equity constrains financing options, raises solvency concerns in stress scenarios, and reduces the company's balance‑sheet buffer against clinical or regulatory setbacks.
Pre‑commercial With Effectively Zero RevenueThe company remains pre‑commercial with essentially no recurring revenue, leaving all value dependent on successful clinical development and future commercialization. This structural absence of operating revenue keeps cash‑flow visibility low and heightens dependence on external capital.
Persistent Negative Free Cash Flow; Funding DependenceFree cash flow is consistently negative and, despite improvement, the company continues to rely on external financing to proceed with its Phase 3 program. This structural funding reliance increases execution risk, potential dilution, and vulnerability to adverse market conditions when capital is needed.
Beyondspring News
BYSI FAQ
What was Beyondspring Inc’s price range in the past 12 months?
Beyondspring Inc lowest stock price was $0.99 and its highest was $2.44 in the past 12 months.
What is Beyondspring Inc’s market cap?
Beyondspring Inc’s market cap is $46.47M.
When is Beyondspring Inc’s upcoming earnings report date?
Beyondspring Inc’s upcoming earnings report date is Sep 04, 2026 which is in 34 days.
How were Beyondspring Inc’s earnings last quarter?
Beyondspring Inc released its earnings results on May 13, 2026. The company reported -$0.052 earnings per share for the quarter, missing the consensus estimate of N/A by -$0.052.
Is Beyondspring Inc overvalued?
According to Wall Street analysts Beyondspring Inc’s price is currently Overvalued.
Does Beyondspring Inc pay dividends?
Beyondspring Inc does not currently pay dividends.
What is Beyondspring Inc’s EPS estimate?
Beyondspring Inc’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Beyondspring Inc have?
Beyondspring Inc has 41,119,820 shares outstanding.
What happened to Beyondspring Inc’s price movement after its last earnings report?
Beyondspring Inc reported an EPS of -$0.052 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went up 4.317%.
Which hedge fund is a major shareholder of Beyondspring Inc?
Currently, no hedge funds are holding shares in BYSI
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Beyondspring Inc
BeyondSpring Inc. is a clinical-stage biopharmaceutical company focused on developing novel cancer treatments. Its flagship product is Plinabulin, a selective immune-modulating and microtubule-binding agent. Plinabulin has successfully advanced through Phase III clinical trials for two distinct applications: the prevention of chemotherapy-induced neutropenia, and the treatment of advanced non-small cell lung cancer. The company is also exploring Plinabulin's efficacy in combination with various immuno-oncology drugs; specifically, alongside nivolumab (a PD-1 antibody) for NSCLC, and with nivolumab and ipilimumab (a CTLA-4 antibody) for small cell lung cancer (SCLC). Furthermore, it is being investigated in conjunction with PD-1 or PD-L1 antibodies and radiation to address a range of cancers. Beyond its lead asset, BeyondSpring's pipeline includes three preclinical-stage small molecule immune agents and a proprietary drug development platform. The company, founded in 2010, maintains its headquarters in New York, New York.
Technical Analysis
Plus Therapeutics
―
X4 Pharmaceuticals
―
ABVC BioPharma
―
Prelude Therapeutics
―
Gain Therapeutics
―
Ownership Overview
10.96% Insiders
2.19% Mutual Funds
9.38% Other Institutional Investors
75.69% Public Companies and
Individual Investors